Preconditioning of Human Decidua Basalis Mesenchymal Stem/ Stromal Cells with Glucose Increased Their Engraftment and Anti-diabetic Properties

Yasser Basmaeil 1 · Manar Al Rashid 1 · Tanvir Khatlani 1 · Manal AlShabibi 2 · Eman Bahattah 2 · Meshan L. Abdullah 3 · Fawaz Abumary 4 · Bill Kalionis 5,6 · Safia Massoudi 7 · Mohammad AbuMaree 1,8

Received: 23 July 2019 / Revised: 10 November 2019 / Accepted: 6 January 2020 / Published online: 19 February 2020
© The Author(s) 2020

Abstract
BACKGROUND: Mesenchymal stem/stromal cells (MSCs) from the decidua basalis (DBMSCs) of the human placenta have important functions that make them potential candidates for cellular therapy. Previously, we showed that DBMSC functions do not change significantly in a high oxidative stress environment, which was induced by hydrogen peroxide (H2O2) and immune cells. Here, we studied the consequences of glucose, another oxidative stress inducer, on the phenotypic and functional changes in DBMSCs.

METHODS: DBMSCs were exposed to a high level of glucose, and its effect on DBMSC phenotypic and functional properties was determined. DBMSC expression of oxidative stress and immune molecules after exposure to glucose were also identified.

RESULTS: Conditioning of DBMSCs with glucose improved their adhesion and invasion. Glucose also increased DBMSC expression of genes with survival, proliferation, migration, invasion, anti-inflammatory, anti-chemoattractant and antimicrobial properties. In addition, DBMSC expression of B7H4, an inhibitor of T cell proliferation was also enhanced by glucose. Interestingly, glucose modulated DBMSC expression of genes involved in insulin secretion and prevention of diabetes.

CONCLUSION: These data show the potentially beneficial effects of glucose on DBMSC functions. Preconditioning of DBMSCs with glucose may therefore be a rational strategy for increasing their therapeutic potential by enhancing their engraftment efficiency. In addition, glucose may program DBMSCs into insulin producing cells with ability to counteract inflammation and infection associated with diabetes. However, future in vitro and in vivo studies are essential to investigate the findings of this study further.

Keywords Placental DBMSCs · Glucose · Cellular functions · Gene expression

1 Introduction

Mesenchymal stem/stromal cells (MSCs) are isolated from many human adult organs, including the placenta [1–3]. MSCs have multipotent differentiation potential [1–3] and possess immune-modulatory properties [4–7], which are essential for tissue restoration. Therefore, MSCs are
considered attractive potential therapeutic agents to treat human diseases including diabetes, hypertension, and atherosclerosis [8–10]. In these inflammatory diseases, the environment is characterized by high levels of oxidative stress and inflammation. Consequently, for successful use of MSCs in these diseases, MSCs must maintain their normal functional activities to repair injured tissues in hostile microenvironments associated with oxidatively stress and inflammation. MSCs that cannot resist the toxic environment, are likely to have reduced therapeutic potential [11].

Recently, we reported the isolation and phenotypic characteristics of MSCs from the maternal decidua basalis tissue (DBMSCs) of human term placenta [1]. Human pregnancy is a condition where the maternal tissues and circulation are exposed to high levels of oxidative stress. DBMSCs in the maternal tissue of decidua basalis are a vascular microenvironment (i.e. niche), and are continuously exposed to high levels of oxidative stress products in the maternal circulation [12]. As a result, DBMSCs are conditioned to resist oxidative stress, as previously reported [13]. In a recent study, we showed that DBMSCs survive the harsh oxidative environment induced by high concentrations of H2O2, and that preconditioning of DBMSCs with H2O2 improved their functional activities [14]. In addition, that preconditioning of DBMSCs with H2O2 modulated their expression of genes with important cellular functions [14]. Therefore, preconditioning of DBMSCs appears to be a rational approach for increase the efficiency of stem cell therapies associated with inflammatory diseases. In this study, we examined the functional responses of DBMSCs to another oxidative stress mediator; glucose. We exposed DBMSCs to high level of glucose and their phenotypic and functional properties were then assessed. We found that DBMSCs survived the harsh environment provided by high level of glucose, and that preconditioning of DBMSCs with glucose increased important functions, including adhesion and invasion. In addition, preconditioning of DBMSCs with glucose enhanced their expression of genes associated with various cellular functions including survival, proliferation, migration, invasion, immune modulation and microbial clearance. Glucose also increased DBMSC expression of B7H4, an immune protein with ability to inhibit T cell proliferation. Finally, DBMSC expression of genes involved in insulin secretion and prevention of diabetes was also modulated by glucose. These data indicate that glucose increases functions associated with engraftment of DBMSCs, and induced beneficial phenotypic changes in DBMSCs. We conclude that DBMSCs are potential candidate for the treatment of diabetes through a mechanism involving the reduction of inflammation and the secretion of insulin to lower glucose levels. However, more studies are essential to confirm these findings in vitro and in vivo.

2 Materials and methods

2.1 Ethical approval and the collection of tissues (human placenta and umbilical cord tissues)

This study was approved by the institutional review board (Reference # IRBC/246/13) at the King Abdullah International Medical Research Centre (KAIMRC). Human placenta and umbilical cord tissues were obtained from term, uncomplicated and healthy pregnancies (pregnant women have no medical problems, such as gestational diabetes or any other types of diabetes) after written consent from the donors. All clinical and experimental techniques in this study were conducted as per the guidelines and regulations of the KAIMRC. Placental tissues were immediately processed.

2.2 Isolation and culture of DBMSCs and HUVEC (human umbilical vein endothelial cells)

DBMSCs were isolated from the decidua basalis which remains attached to the maternal side of the human term placenta after delivery, while HUVEC were isolated from umbilical cord veins as previously described by us [1, 16].
DBMSCs were cultured in a complete DBMSC culture medium [DMEM-F12 medium containing 10% MSCFBS (Mesenchymal Stem Cell certified fetal bovine serum, catalogue number 12-662-011, Life Technologies, Grand Island, NY, USA), and antibiotics (100 μg/mL streptomycin and 100 U/mL penicillin)], while HUVEC were cultured in a complete endothelial cell growth medium (Catalogue number PCS-100-041TM, ATCC, Manassas, VA, USA). Cells (DBMSCs and HUVEC) were incubated at 37 °C in a humidified atmosphere containing 5% CO2 and 95% air (a cell culture incubator). DBMSCs (passage 3) and HUVEC (passages 3–5) of a total of 30 placentae and umbilical cords, respectively, were used in this study.

2.3 DBMSC proliferation and adhesion in response to glucose

DBMSC treatment groups consist of three groups as described in supplementary Table 1 and illustrated in Fig. 1A–C. The xCELLigence system (RTCA-DP version; Roche Diagnostics, Mannheim, Germany) was used to evaluate the adhesion and proliferation of HUVEC as we previously described [15–18]. Briefly, 2 × 104 DBMSCs
were seeded in a complete DBMSC culture medium (as described above) containing different concentrations (25–400 mM) of glucose (Prince Care Pharma Pvt. Ltd, India) in 16-well culture plates (Catalogue number 05469813001, E-Plate 16, Roche Diagnostics). The culture plates were then placed in the xCELLigence system at 37°C in a cell culture incubator and the DBMSC cell index was then monitored. The data for cell adhesion (at 2 h) and proliferation (24–72 h) was determined as previously described [15–18]. DBMSC viability was determined by Trypan blue exclusion. Each experiment was performed in triplicate and repeated with five independent DBMSC (passage 3) preparations.

2.4 DBMSC migration in response to glucose

DBMSC migration was examined using the xCELLigence system and 16-well plates (Catalogue number 05665825001, CIM-16, Roche Diagnostics) as we described previously [15–18]. DBMSC treatment groups consist of three groups as described in supplementry Table 2 and illustrated in Fig. 3A–C. Briefly, 2 × 10^4 DBMSCs were seeded in the upper chamber, and the migration of cells was then monitored by the xCELLigence system [15–18]. The data were then expressed as a cell index value at 24 h. DBMSC migration with 30% FBS and without FBS served as positive and negative controls, respectively. Each experiment was performed and repeated as described above.

2.5 DBMSC invasion under the effect of glucose

We evaluated the effect of glucose on the ability of DBMSCs to invade through a monolayer of endothelial cells using the xCELLigence system. Briefly, 2 × 10^4 HUVEC seeded in a complete endothelial cell growth medium in a 16-well culture E-Plate (as described above) until cells reached a growth plateau (20 h). Different treatments of DBMSCs (supplementary Table 3) were then added to the monolayer of endothelial cells. At 10 h, the data for the invasion recorded and expressed as a cell index (mean ± standard error). The rate of cell invasion was determined by calculating the normalized cell index at pausing time (20 h) of HUVEC growth.

2.6 Gene expression by real-time polymerase chain reaction (RT-PCR)

DBMSC expression of 84 genes related to Human Oxidative Stress (Catalogue # PAHS-065ZD, Qiagen, Hilden, Germany) was identified using our previously published method [1, 14, 15, 18]. Total RNA was extracted from DBMSCs pretreated with 200 mM glucose for 72 h, and cDNA was then synthesized and used in a QuantiTect Primer Assay (Qiagen, Hilden, Germany). The real-time polymerase chain reaction (RT-PCR) was performed in triplicate on the CFX96 real-time PCR detection system (BIO-RAD, Hercules, CA, USA), and the data was then analysed as previously described [1, 14, 15, 18]. The ΔΔ^-2 values were then calculated to express the results as fold changes. The relative expression of internal controls (house-keeping genes) were used as provided in the kit. Experiments were performed in triplicate and repeated three times using DBMSCs prepared from three independent placentae.

2.7 Flow cytometry

DBMSCs (1 × 10^5) were stained with antibodies for ICAM-1, IL-12, and B7H4 for 30 min and then flow cytometry was performed as previously described [1]. Negative controls were cells stained with FITC or PE-labelled mouse IgG isotype antibody.

2.8 Statistical analysis

GraphPad Prism 5 was used to analyze data using non-parametric tests (Mann–Whitney U and Kruskal–Wallis). Data were deemed statistically significant if p < 0.05.
3 Results

3.1 Glucose effect on DBMSC proliferation

DBMSCs were isolated using our established published method [1, 14–16] to assess the effect of glucose on their proliferation using the xCELLigence system. At 24 h, and as compared to untreated DBMSCs, the proliferation of DBMSCs unchanged at 25 mM glucose ($p > 0.05$), significantly increased at 50 and 200 mM glucose ($p < 0.05$), and was significantly reduced at 400 mM glucose, $p < 0.05$ (Fig. 1D). At 48 h, and as compared to untreated DBMSCs, the proliferation of DBMSCs unchanged at 50 mM glucose ($p > 0.05$), significantly increased at 200 mM glucose ($p < 0.05$), and significantly reduced at 25 and 400 mM glucose, $p < 0.05$ (Fig. 1E). Finally, at 72 h, and as compared to untreated DBMSCs, the proliferation of DBMSCs, significantly increased at 200 mM glucose ($p < 0.05$) but was significantly reduced at 25, 50 and 400 mM glucose, $p < 0.05$ (Fig. 1F). The viability of DBMSC treated with glucose (25–200 mM) for 72 h was >90% as determine by Trypan Blue exclusion. At 96 h, treatment with glucose (25–200 mM) reduced the viability of DBMSCs (< 50%) while the treatment with 400 mM glucose reduced the viability of DBMSCs (< 50%) at all examined culture times (24–72 h) (supplementary Fig. 1). Based on the results obtained above, the exposure time of 72 h and glucose at concentration of glucose (200 mM) was selected to evaluate the effect of glucose on DBMSC functions.

3.2 Reversibility of glucose effect on DBMSC proliferation

To evaluate the reversibility of the glucose effect on DBMSC proliferation, DBMSCs were initially cultured with 200 mM glucose for 72 h and their proliferation was then determined using the xCELLigence system. As
compared to untreated DBMSCs and DBMSC-treated with 200 mM glucose during the proliferation experiment [200 (pre)], the proliferation of DBMSC pretreated with 200 mM glucose [200 (pre)] significantly reduced ($p < 0.05$) at all examined culture times (24–72 h), (Fig. 1G–I). These results show the effect of glucose on DBMSC proliferation is reversible.

### 3.3 Glucose effect on DBMSC adhesion

To study the effects of glucose on the adhesion of DBMSCs, DBMSCs were cultured with 200 mM glucose and their adhesion was then determined using the xCELLigence system. At 2 h, and as compared to untreated DBMSCs, the adhesion of DBMSCs unchanged after treatment with 200 mM glucose, $p > 0.05$ (Fig. 2).

We also evaluated the reversibility of glucose effects on DBMSC adhesion. DBMSCs were initially cultured with 200 mM glucose for 72 h and their adhesion was then determined using the xCELLigence system. After 2 h, and as compared to untreated DBMSCs, and DBMSC-treated with 200 mM glucose during the experiment [200 (I)], the adhesion of DBMSCs pretreated with 200 mM glucose [200 (pre)] significantly increased, $p < 0.05$ (Fig. 2).

### 3.4 Glucose effect on DBMSC migration

To further study the effect of glucose on DBMSC functions, the migration of DBMSCs was monitored using the xCELLigence system. At 24 h and as compared to untreated DBMSCs (DB), the migration of DBMSCs in response to 200 mM glucose [DB (To 200)] significantly increased, $p < 0.05$ (Fig. 3D).

We also evaluated the reversibility of glucose effects on DBMSC migration, DBMSCs were initially cultured with 200 mM glucose for 72 h and their migration was then determined using the xCELLigence system. The migration of DBMSC-pretreated with 200 mM glucose for 72 h in response to 200 mM glucose [Pre-DB (To 200)] significantly increased ($p < 0.05$) as compared to untreated DBMSCs (DB) but unchanged as compared to DBMSCs-migrated in response to 200 mM glucose [DB (To 200)], $p > 0.05$ (Fig. 3D). These results show the effect of glucose on DBMSC migration is irreversible.

### 3.5 Glucose effect on DBMSC invasion

We also evaluated the effect of glucose on DBMSC invasion through endothelial cells using the xCELLigence Real-Time Cell Analyser. In the xCELLigence Real-Time system, increased invasion is defined as an increase in the cell index due to the infiltration of HUVEC monolayer by DBMSCs and this therefore causing detachment of HUVEC while the increased of DBMSC adhesion is reflected by the increased of cell index defining the increase in cell invasion. At 10 h and as compared to untreated DBMSCs and DBMSCs cultured with 200 mM glucose, the pre-treatment of DBMSCs with 200 mM glucose for 72 h [200 (Pre)] significantly increased DBMSC invasion, $p < 0.05$ while the addition of 200 mM glucose [200 (in)] during the course of invasion experiment had no significant effect on DBMSC invasion, $p > 0.05$ (Fig. 3E).

### 3.6 Glucose increases DBMSC expression of adhesion and anti-inflammatory markers

To evaluate the modulatory effects of glucose on DBMSC functions, a variety of immune proteins important in DBMSC functions were studied by flow cytometry and expression recorded as median fluorescence intensity. As compared to untreated DBMSCs, after incubation with increased the expression of B7H4, as compared untreated DBMSCs. Each experiment was performed in triplicate and repeated with five independent DBMSC (passage 3) preparations. $p < 0.05$. Bars represent standard errors.

---

**Fig. 4** Flow cytometric analysis of DBMSC expression of immune markers. A-C The treatment with 200 mM glucose significantly increased the DBMSCs [200 (pre)] expression of ICAM-1, had no significant effect on IL-12 expression, $p > 0.05$, and significantly
Glucose effects on DBMSC expression of oxidative genes with survival, anti-apoptotic, proliferation, and migration properties. DBMSCs were untreated (DBMSC) or treated with 200 mM glucose (TDBMSC) for 72 h.

| #  | Gene symbol | Gene full name | DBMSC Mean ΔA−2 values | TDBMSC Mean ΔA−2 values | Fold change (TDBMSC vs. DBMSC) | Biological properties |
|----|-------------|----------------|------------------------|--------------------------|-------------------------------|------------------------|
| 1  | GPX2        | Glutathione peroxidase 2 | 1 | 5 | 1 fold | 1. Survival property |
| 2  | GPX3        | Glutathione peroxidase 3 | 1 | 16 | 16 fold | 2. Anti-apoptotic property |
| 3  | GPX4        | Glutathione peroxidase 4 | 1 | 60 | 60 fold | 3. Migration property |
| 4  | GPX7        | Glutathione peroxidase 7 | 1 | 4 | 4 fold | 4. Invasion property |
| 5  | PRDX1       | Peroxiredoxin 1 | 1 | 1.5 | 1.5 fold | 1. Survival property |
| 6  | PRDX4       | Peroxiredoxin 4 | 1 | 2.52 | 2.52 fold | 2. Migration property |
| 7  | PRDX5       | Peroxiredoxin 5 | 1 | 2.63 | 2.63 fold | 3. Invasion property |
| 8  | PRDX6       | Peroxiredoxin 6 | 1 | 40 | 40 fold | 1. Survival property |
| 9  | HMOX1       | Heme oxygenase-1 | 1 | 3.18 | 3.18 fold | 1. Survival property |
| 10 | ALB         | Albumin | 1 | 3 | 3 fold | Survival property |
| 11 | OXR1        | Oxidation resistance 1 | 1 | 12 | 12 fold | 2. Migration property |
| 12 | KRT1        | Keratin 1 | 1 | 2618 | 2618 fold | 1. Anti-apoptotic property |
| 13 | NQO1        | NAD(P)H dehydrogenase, quinone 1 | 1 | 21 | 21 fold | 2. Migration property |
| 14 | MB          | Myoglobin | 1 | 707 | 707 fold | 3. Invasion property |
| 15 | STK25       | Serine/threonine kinase 25 | 1 | 77 | 77 fold | 1. Proliferation property |
| 16 | ALOX12      | Arachidonate 12-lipoxygenase | 1 | 519 | 519 fold | 2. Migration property |
| 17 | TFII-I      | General transcription factor 2I (GTF2I) | 1 | 60 | 60 fold | 3. Invasion property |
| 18 | FOXM1       | Forkhead box M1 | 1 | 34 | 34 fold | 1. Proliferation property |
| 19 | BNIP3       | BCL2/adenovirus E1B 19 kDa interacting protein 3 | 1 | 49 | 49 fold | 2. Migration property |

200 mM glucose for 72 h [200 (pre)], DBMSC expression of ICAM-1 and B7H4, significantly increased $p < 0.05$ (Fig. 4), while the expression of IL-12 by DBMSCs did not significantly change, $p > 0.05$ (Fig. 4B).

### 3.7 Glucose modulated the expression of genes important in DBMSC functions

The expression of oxidative stress-associated genes by DBMSCs was studied after culturing DBMSCs with 200 mM glucose for 72 h, and then analysed and assessed using the RT-PCR. Results show that glucose modulated DBMSC expression of variety of genes associated with many cellular functions as compared to untreated DBMSC as shown in Tables 1, 2, 3, 4 and 5.

### 4 Discussion

Recently, we reported the therapeutic potential of DBMSCs to treat inflammatory diseases, such as atherosclerosis and cancer [14–16, 19]. Diabetes is another inflammatory diseases [8] where high levels of glucose (an oxidative stress mediator) cause cellular and tissue damage [20–23]. Therefore, for an effective application of DBMSCs in diabetes, it is important for DBMSCs maintain their normal reparative properties when exposed to high levels of glucose. Here, we studied the functional and phenotypic changes of DBMSCs in response to glucose.

First, we examined the effect of different glucose concentrations on the survival of DBMSCs. We report that
DBMSCs survive in high levels of 200 mM glucose even when cultured for long periods. DBMSCs also showed increased proliferation potential at high levels of glucose (Fig. 1D–F), via a reversible mechanism (Fig. 1G–I). This contrasts with our previous finding in which MSCs from the chorionic villi of human placentae (pMSCs) show a reduction in their proliferation under the effect of glucose [18]. This may reflect DBMSC adaption to the elevated oxidative stress levels in normal pregnancy, as a result of their vascular microenvironment where they are directly or indirectly exposed to factors in maternal pregnant blood, which contains high level of oxidative stress mediators [24]. On the other hand, pMSCs in the chorionic vascular niche, are exposed to the fetal circulation, which contains relatively reduced levels of oxidative stress throughout normal pregnancy [13, 25].

Glucose also induced DBMSC expression of genes associated with survival, anti-apoptotic [26–37], and proliferation [38–40] as shown in Table 1. These molecules may prevent the damaging effects of glucose on DBMSCs. However, this needs further investigation to confirm the protective roles of these molecules in the survival and proliferation of DBMSCs from glucose. In this study, preconditioning of DBMSCs with glucose enhanced their adhesion (Fig. 2) possibly via ICAM-1 (Fig. 4A). This is consistent with our previous study which showed that DBMSCs preconditioned with H$_2$O$_2$ showed increased adhesion [14]. Other studies also support our finding, where preconditioning of hematopoietic stem cells with H$_2$O$_2$ also increased their adhesion in vitro and in vivo [41]. Adhesion is the first important biological process required for a successful stem cell engraftment [42, 43]. Migration and invasion of MSCs are other important biological processes that occur during MSC engraftment in a disease environment with high level of oxidative stress mediators [42, 43]. We found that DBMSCs preconditioned with glucose improved their migration (Fig. 3D). This effect is similar to the effect of H$_2$O$_2$ on the migration of DBMSCs [14], MSCs from the chorionic villi [44] and bone marrow [45]. DBMSCs preconditioned with glucose also improved their invasion (Fig. 3E) via a mechanism that may involve the induction of a number of genes known for their migratory [26–28, 47, 48], and invasive properties [26–28, 47, 48], Table 1. These results demonstrate that the engraftment properties of DBMSCs can be improved by glucose pretreatment, possibly via these genes. Thus, preconditioning DBMSCs could be valuable component of cell-based therapies that must act in high oxidative stress environments. However, a future mechanistic study is necessary to confirm this further.

### Table 2. Glucose effects on DBMSC expression of oxidative genes with pro-oxidant and antioxidant properties. DBMSCs were untreated (DBMSC) or treated with 200 mM glucose (TDBMSC) for 72 h.

| # | Gene symbol | Gene full name | DBMSC Mean ΔΔ$^{-2}$ values | TDBMSC Mean ΔΔ$^{-2}$ values | Fold change (TDBMSC vs. DBMSC) | Biological properties |
|---|-------------|----------------|-----------------------------|-----------------------------|---------------------------------|-----------------------|
| 1 | NOX2 (CYBB) | Cytochrome b-245, β polypeptide | 1 11.62 11.62 fold | ↑ Pro-oxidant property |
| 2 | NOX4 | NADPH oxidase 4 | 1 9.89 > 9 fold | ↑ |
| 3 | NOX5 | NADPH oxidase 5 | 1 14 14 fold | ↑ |
| 4 | DUOX1 | Dual oxidase 1 | 1 2 2 fold | ↑ |
| 5 | DUOX2 | Dual oxidase 2 | 1 52 52 fold | ↑ |
| 6 | NCF1 | Neutrophil cytosolic factor 1 | 1 6.59 6.59 fold | ↑ |
| 7 | NCF2 | Neutrophil cytosolic factor 2 | 1 50 50 fold | ↑ |
| 8 | ALOX12 | Arachidonate 12-lipoxygenase | 1 519 519 fold | ↑ |
| 9 | AOX1 | Aldehyde oxidase 1 | 1 34 34 fold | ↑ |
| 10 | GPX1 | Glutathione peroxidase 1 | 1 0.10 10 fold | ↓ Anti-oxidant property |
| 11 | GPX5 | Glutathione peroxidase 5 | 1 13 13 fold | ↓ |
| 12 | GPX6 | Glutathione peroxidase 6 | 1 0.02 50 fold | ↓ |
| 13 | PRDX2 | Peroxiredoxin 2 | 1 0.02 50 fold | ↓ |
| 14 | PRDX3 | Peroxiredoxin 3 | 1 0.39 > 2.50 fold | ↓ |
| 15 | CAT | Catalase | 1 0.56 > 1.70 fold | ↓ |
| 16 | SOD1 | Superoxide dismutase 1 | 1 0.016 > 62 fold | ↓ |
| 17 | SOD2 | Superoxide dismutase 2 | 1 0.052 > 19 fold | ↓ |
| 18 | TTN | Titin | 1 0.20 5 fold | ↓ |
In the pancreatic beta islets, the pro-oxidant enzymes (i.e. NOX1-5 and DUOX1-2) increase the production of the reactive oxygen specie (ROS) superoxide, which induces insulin secretion [52–56]. The excessive accumulation of ROS causes beta cell damage, which can be prevented by the antioxidant enzymes (i.e. GPX, CAT and SOD), which act as ROS scavengers, and therefore inhibit insulin secretion [52–56]. In this study, glucose induced and reduced DBMSC expression of genes with pro-oxidant [39, 57, 58] and anti-oxidant properties, respectively [59], Table 2. Thus, indicating that glucose may direct DBMSCs to activate pathways associated with insulin secretion. This postulate is supported by the finding that glucose also induced DBMSC expression of albumin and NOS2, which are associated with insulin secretion [32, 60]. In addition, glucose also reduced DBMSC expression of PXDN, a molecule that triggers diabetes, Table 4 [61].

Generally, a basal level of ROS is required to stimulate basic cellular biological activities (i.e. proliferation, migration, and invasion). ROS is also required for insulin secretion by beta cells. As discussed above, the high level of ROS damages tissue, and consequently this is avoided by the antioxidant enzymes which are produced to scavenge ROS [62]. Glucose simultaneously induced DBMSC expression of both pro-oxidant (Table 4) and anti-oxidant genes [40, 50, 63–66], Table 4. Therefore, DBMSCs may respond to glucose induction of ROS by generating antioxidants to prevent cellular damage and also to regulate insulin secretion probably by inducing the expression of UCP2 (Table 4), which has anti-insulin secretion activity [63].

### Table 3

| # | Gene symbol | Gene full name | DBMSC Mean $\Delta\Delta^{\text{CT}}$ values | TDBMSC Mean $\Delta\Delta^{\text{CT}}$ values | Fold change (TDBMSC vs. DBMSC) $p < 0.05$ | Biological properties |
|---|-------------|----------------|---------------------------------------------|---------------------------------------------|-------------------------------------------|----------------------|
| 1 | GPX2        | Glutathione peroxidase 2 | 1                                           | 5                                           | 1 fold                                    | Anti-oxidant property |
| 2 | GPX3        | Glutathione peroxidase 3 | 1                                           | 16                                          | 16 fold                                   | 2. Anti-inflammatory property |
| 3 | GPX4        | Glutathione peroxidase 4 | 1                                           | 60                                          | 60 fold                                   |                       |
| 4 | GPX7        | Glutathione peroxidase 7 | 1                                           | 4                                           | 4 fold                                    |                       |
| 5 | UCP2        | Uncoupling protein 2    | 1                                           | 7                                           | 7 fold                                    |                       |
| 6 | SEPP1       | Selenoprotein P, plasma, 1 | 1                                           | 10                                          | 10 fold                                   |                       |
| 7 | PRDX1       | Peroxiredoxin 1        | 1                                           | 1.5                                         | 1.5 fold                                   | Anti-oxidant property |
| 8 | PRDX4       | Peroxiredoxin 4        | 1                                           | 2.52                                        | 2.52 fold                                   |                       |
| 9 | PRDX5       | Peroxiredoxin 5        | 1                                           | 2.63                                        | 2.63 fold                                   |                       |
| 10| PRDX6       | Peroxiredoxin 6        | 1                                           | 40                                          | 40 fold                                    |                       |
| 11| TPO         | Thyroid peroxidase     | 1                                           | 2.48                                        | 2.48 fold                                   |                       |
| 12| TFII-I (GTF2I) | General transcription factor 2I | 1                                           | 60                                          | 60 fold                                    |                       |
| 13| BNIP3       | BCL2/adenovirus E1B 19 kDa interacting protein 3 | 1                                           | 49                                          | 49 fold                                    |                       |
| 14| PNKP        | Polynucleotide kinase 3'-phosphatase | 1                                           | 2.75                                        | 2.75 fold                                   |                       |
| 15| SOD3        | Superoxide dismutase 3 | 1                                           | 4.45                                        | 4.45 fold                                   |                       |
| 16| HMOX1       | Heme oxygenase- 1      | 1                                           | 3.18                                        | 3.18 fold                                   | Anti-inflammatory property |
| 17| MT3         | Metallothionein 3      | 1                                           | 124                                         | 124 fold                                   | Anti-inflammatory property |
| 18| GSR         | Glutathione reductase  | 1                                           | 2.55                                        | 2.55 fold                                   |                       |
| 19| DUSP1       | Dual specificity phosphatase 1 | 1                                           | 2                                           | 2 fold                                    |                       |
| 20| KRT1        | Keratin 1              | 1                                           | 2618                                        | 2618 fold                                   |                       |
| 21| NQO1        | NAD(P)H dehydrogenase, quinone 1 | 1                                           | 21                                          | 21 fold                                    |                       |
| 22| SIRT2       | Sirtuin 2              | 1                                           | 2.99                                        | 2.99 fold                                   |                       |
| 23| SFTPD       | Surfactant protein D   | 1                                           | 114                                         | 114 fold                                   | Anti-inflammatory property |
| 24| MBL2        | Mannose-binding lectin (protein C) 2 | 1                                           | 6.34                                        | 6.34 fold                                   | Anti-inflammatory property |

In the pancreatic beta islets, the pro-oxidant enzymes (i.e. NOX1-5 and DUOX1-2) increase the production of the reactive oxygen specie (ROS) superoxide, which induces insulin secretion [52–56]. The excessive accumulation of ROS causes beta cell damage, which can be prevented by the antioxidant enzymes (i.e. GPX, CAT and SOD), which act as ROS scavengers, and therefore inhibit insulin secretion [52–56]. In this study, glucose induced and reduced DBMSC expression of genes with pro-oxidant [39, 57, 58] and anti-oxidant properties, respectively [59], Table 2. Thus, indicating that glucose may direct DBMSCs to activate pathways associated with insulin secretion. This postulate is supported by the finding that glucose also induced DBMSC expression of albumin and NOS2, which are associated with insulin secretion [32, 60]. In addition, glucose also reduced DBMSC expression of PXDN, a molecule that triggers diabetes, Table 4 [61].

Generally, a basal level of ROS is required to stimulate basic cellular biological activities (i.e. proliferation, migration, and invasion). ROS is also required for insulin secretion by beta cells. As discussed above, the high level of ROS damages tissue, and consequently this is avoided by the antioxidant enzymes which are produced to scavenge ROS [62]. Glucose simultaneously induced DBMSC expression of both pro-oxidant (Table 4) and anti-oxidant genes [40, 50, 63–66], Table 4. Therefore, DBMSCs may respond to glucose induction of ROS by generating antioxidants to prevent cellular damage and also to regulate insulin secretion probably by inducing the expression of UCP2 (Table 4), which has anti-insulin secretion activity [63].
In diabetes, the oxidative stress mediators generated by the high level of glucose, stimulate the recruitment of immune cells to the site of tissue injury, and this in return will intensify tissue damage [67]. One of the therapeutic strategies, is to reduce the recruitment of immune cells to the injured tissue. In this study, glucose reduced DBMSCs expression of thioredoxin (Table 4), an oxidative stress molecule that increases the recruitment of immune cells [67]. Glucose also increased the anti-inflammatory properties of DBMSCs by increasing their expression of anti-inflammatory genes [26, 31, 34, 35, 63, 64, 68–74] (Table 3), and also by reducing their expression of pro-inflammatory genes including MGST3 and COX2 [75–77]. This finding is important, because these anti-inflammatory molecules reduce the recruitment of immune cells [70]. These results indicate that DBMSCs may function as an anti-chemoattractant agent to reduce the recruitment of immune cells to the injured tissues in inflammatory diseases. The property of DBMSCs to ameliorate inflammation is further confirmed by their enhanced expression of B7-H4 in response to glucose (Fig. 4). B7-H4 is a protein that inhibits T-cell proliferation [78], suggesting that DBMSCs may inhibit T cell proliferation, and thus reduce inflammation.

High levels of glucose also causes immune dysfunction that results in a reduction in the antimicrobial activity of the immune cells in diabetic patients, and therefore these patients are at a higher risk to bacterial infection [79]. In this study, glucose induced DBMSC expression of antibacterial genes, [71, 73], Table 3. Collectively, these results suggest that DBMSCs may have the potential to treat inflammatory diseases, such as diabetes, by ameliorating inflammation and also by preventing infection associated with hyperglycaemia.

This is the first study to show the beneficial effects of glucose on DBMSC functions. Preconditioning of DBMSCs with glucose may increase their therapeutic potential by enhancing their engraftment efficiency.

### Table 4 Glucose effects on DBMSC expression of oxidative genes. DBMSCs were untreated (DBMSC) or treated with 200 mM glucose (TDBMSC) for 72 h

| # | Gene symbol | Gene full name | DBMSC Mean ΔΔ^−2 values | TDBMSC Mean ΔΔ^−2 values | Fold change (TDBMSC vs. DBMSC) | p < 0.05 | Biological properties |
|---|-------------|---------------|--------------------------|--------------------------|--------------------------------|----------|----------------------|
| 1 | CYGB | Cytoglobin | 1 | 0.56 | >1.70 fold | ↓ | Cytoprotective property |
| 2 | TXNRD2 | Thioredoxin reductase 2 | 1 | 18 | 18 fold | ↑ | Anti-growth property |
| 3 | NOS2 | Nitric oxide synthase 2 | 1 | 15.81 | 15.81 fold | ↑ | Inflammatory property |
| 4 | MGST3 | Microsomal glutathione S-transferase 3 | 1 | 0.34 | >2.9 fold | ↓ | |
| 5 | COX1 | Cyclooxygenase 1 | 1 | 2 | 2 fold | ↑ | |
| 6 | COX2 | Cyclooxygenase 2 | 1 | 0.0077 | >129 fold | ↓ | |
| 7 | NOX4 | NADPH oxidase 4 | 1 | 9.89 | >9 fold | ↑ | |
| 8 | NOX5 | NADPH oxidase 5 | 1 | 14 | 14 fold | ↑ | |
| 9 | GSTZ1 | Glutathione transferase zeta 1 | 1 | 0.0002 | 5000 fold | ↓ | Anti-inflammatory property |
| 10 | GSTP1 | Glutathione S-transferase pi 1 | 1 | 0.66 | >16 | ↓ | Anti-apoptotic Property |
| 11 | UCP2 | Uncoupling protein 2 | 1 | 7 | 7 fold | ↑ | Inhibits Insulin Secretion |
| 12 | PXDN | Peroxidasin homolog | 1 | 0.24 | >4 fold | ↓ | Triggers Diabetes |
| 13 | BNIP3 | BCL2/adenovirus E1B 19 kDa interacting protein 3 | 1 | 49 | 49 fold | ↑ | Pro-apoptotic property |
| 14 | PRNP | Prion protein | 1 | 0.05 | 20 fold | ↓ | Anti-inflammatory property |
| 15 | HSP70-1A | Heat shock 70 kDa protein 1A | 1 | 0.05 | 20 fold | ↓ | |
| 16 | PDLIM1 | PDZ and LIM domain 1 | 1 | 0.01 | 100 fold | ↓ | |
| 17 | TTN | Thioredoxin | 1 | 0.10 | 10 fold | ↓ | Chemoattractant property |
| 18 | SOD1 | Superoxide dismutase 1 | 1 | 0.016 | >62 fold | ↓ | Antioxidant property |
| 19 | SOD2 | Superoxide dismutase 2 | 1 | 0.052 | >19 fold | ↓ | Anti-inflammatory property |
| 20 | LPO | Lactoperoxidase | 1 | 0.029 | >34 fold | ↓ | Anti-microbial property |

Springer
In addition, the induction of ROS in DBMSCs by glucose may program these cells into insulin producing cells with ability to counteract inflammation and infection associated with diabetes (Fig. 5). However, future in vitro and in vivo studies are essential to investigate the findings of this study further.

**Acknowledgements** We acknowledge King Abdul Aziz Medical City for providing us with placentae. Grants from KAIMRC (Grant No. R17/202) supported this study.

**Author Contributions** MHA and TK proposed and supervised the project. MHA and TK designed the experiments. YSB, MAR, MAA, and EB performed the experiments. MHA, YSB and TK analysed the data. YSB, TK and MHA wrote the manuscript. MHA, YSB, TK, MLA, BK, SM and FMA, contributed to data analysis and interpretation of results. All authors reviewed the manuscript.

**Compliance with ethical standards**

**Conflict of interest** No competing financial interests exist. The authors declare that there is no conflict of interests regarding the publication of this paper.
Ethical statement The institutional review board (IRB) at King Abdullah International Medical Research Centre (KAIMRC), Saudi Arabia approved this study. Samples (i.e. placenta and umbilical cords) were obtained from uncomplicated human pregnancies (38–40 gestational weeks) following informed patient consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Abomaray FM, Al Jumah MA, Alsaad KO, Jawdat D, Al Khaldi A, AlAskar AS, et al. Phenotypic and functional characterization of mesenchymal stem/multipotent stromal cells from decidua basalis of human term placenta. Stem Cells Int. 2016;2016:5184601.

2. Abumaree MH, Abomaray FM, Alshehri NA, Almutairi A, AlAskar AS, Kalionis B, et al. Phenotypic and functional characterization of mesenchymal stem/multipotent stromal cells from decidua parietalis of human term placenta. Reprod Sci. 2016;23:1193–207.

3. Abumaree MH, Al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, Al Talabani AA, et al. Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Rev Rep. 2013;9:16–31.

4. Abomaray FM, Al Jumah MA, Kalionis B, AlAskar AS, Al Harthy S, Jawdat D, et al. Human chorionic villous mesenchymal stem cells modify the functions of human dendritic cells, and induce an anti-inflammatory phenotype in CD14+ dendritic cells. Stem Cell Rev Rep. 2015;11:423–41.

5. Abumaree MH, Abomaray FM, Alshabibi MA, AlAskar AS, Kalionis B. Immunomodulatory properties of human placental mesenchymal stem/stromal cells. Placenta. 2017;59:87–95.

6. Abumaree MH, Al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, Abomaray FM, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev Rep. 2013;9:620–41.

7. Al Jumah MA, Abumaree MH. The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). Int J Mol Sci. 2012;13:2928–331.

8. Zang L, Hao H, Liu J, Li Y, Han W, Mu Y. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:36.

9. Li F, Guo X, Chen SY. Function and therapeutic potential of mesenchymal stem cells in atherosclerosis. Front Cardiovasc Med. 2017;4:32.

10. de Mendonca L, Felix NS, Blanco NG, Da Silva JS, Ferreira TP, Abreu SC, et al. Mesenchymal stem cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther. 2017;8:220.

11. Auletta JJ, Cooke KR, Solchaga LA, Deans RJ, van’t Hof W. Regenerative stem cell therapy in allogeneic hematopoietic cell transplantation: current impact and future directions. Biol Blood Marrow Transplant. 2010;16:891–906.

12. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int. 2009;76:831–7.

13. Kusuma GD, Abumaree MH, Pettle MD, Perkins AV, Breennecke SP, Kalionis B. Mesenchymal stem/stromal cells derived from a reproductive tissue niche under oxidative stress have high aldehyde dehydrogenase activity. Stem Cell Rev Rep. 2016;12:285–97.

14. Khatlani T, Algudiri D, Alenzi R, Al Subayil AM, Abomaray FM, Bahattab E, et al. Preconditioning by hydrogen peroxide enhances multiple properties of human decidua basalis mesenchymal stem/multipotent stromal cells. Stem Cells Int. 2018;2018:6480793.

15. Alshabibi MA, Khatlani T, Abomaray FM, AlAskar AS, Kalionis B, Messaoudi SA, et al. Human decidua basalis mesenchymal stem/stromal cells protect endothelial cell functions from oxidative stress induced by hydrogen peroxide and monocytes. Stem Cell Res Ther. 2018;9:275.

16. Alshabibi MA, Al Huqail AJ, Khatlani T, Abomaray FM, Alaskar AS, Alawad AO, et al. Mesenchymal stem/multipotent stromal cells from human decidua basalis reduce endothelial cell activation. Stem Cells Dev. 2017;26:1355–73.

17. Abumaree MH, Hakami M, Abumaree FM, Alshabibi MA, Kalionis B, Al Jumah MA, et al. Human chorionic villous mesenchymal stem/stromal cells modify the effects of oxidative stress on endothelial cell functions. Placenta. 2017;59:74–86.

18. Basmaeil YS, Al Subayil AM, Khatlani T, Bahattab E, Al-Alwan M, Abomaray FM, et al. Human chorionic villous mesenchymal stem/stromal cells protect endothelial cells from injury induced by high level of glucose. Stem Cell Res Ther. 2018;9:238.

19. Abumaree MH, Al Harthy S, Al Subayil AM, Alshabibi MA, Abomaray FM, Khatlani T, et al. Decidua basalis mesenchymal stem cells favor inflammatory M1 macrophage differentiation in vitro. Cells. 2019;8:E173.

20. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436–43.

21. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.

22. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010;11:61–74.

23. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15:44–54.

24. Rajmakers MT, Roes EM, Poston L, Steegers EA, Peters WH. The transient increase of oxidative stress during normal pregnancy is higher and persists after delivery in women with preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2008;138:39–44.

25. Braecke K, Harsem NK, Staff AC. Oxidative stress induced by hydrogen peroxide and monocytes. Stem Cell Rev Rep. 2010;6:560–4.

26. Kost OA, Beznos OV, Davydova NG, Manickam DS, Nikolskaya A, Guller AE, et al. Superoxide dismutase 1 nanozyme for antioxidant status in fetal circulation in preeclampsia. Pediatr Res. 2016;80:6480793.

27. Niu W, Zhang M, Chen H, Wang C, Shi N, Jing X, et al. Peroxiredoxin 1 promotes invasion and migration by regulating epithelial-to-mesenchymal transition during oral carcinogenesis. Oncotarget. 2016;7:47042–51.
28. Taniuchi K, Furihata M, Hanazaki K, Iwasaki S, Tanaka K, Shimizu T, et al. Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity. Pancreas. 2015;44:331–40.

29. Park KR, Yun HM, Yeo IJ, Cho S, Hong JT, Jeong YS. Peroxiredoxin 6 inhibits osteogenetic differentiation and bone formation through human dental pulp stem cells and induces delayed bone development. Antioxid Redox Signal. 2018;30:1969–82.

30. Zhou Y, Cao X, Yang Y, Wang J, Yang W, Ben P, et al. Glutathione S-transferase P1 prevents sepsis-related high mobility group box-1 protein translocation and release. Front Immunol. 2018;9:268.

31. Wenzel P, Rossmann H, Müller C, Kossmann S, Oelze M, Schulz W, et al. Oxidative preconditioning promotes bone marrow mesenchymal stem cells migration and prevents apoptosis. Cell Biol Int. 2009;33:411–8.

32. Kwon J, Wang A, Burke DJ, Boudreau HE, Lekstrom KJ, Korzeniowska A, et al. Peroxiredoxin 6 (Prdx6) supports NADPH oxidase1 (Nox1)-based superoxide generation and cell migration. Free Radic Biol Med. 2016;96:99–115.

33. Zhong C, Zhuang M, Wang X, Li J, Chen Z, Huang Y, et al. NAD(P)H: quinone oxidoreductase 1 and its reductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol. 2012;12:39–45.

34. Pi J, Bai Y, Zhang Q, Wong V, Floering LM, Daniel K, et al. Oxr1 is essential for protection against oxidative stress-induced neurodegeneration. PLoS Genet. 2011;7:e1002338.

35. Roth W, Kumar V, Beer HD, Richter M, Wohlenberg C, Reuter M, et al. A novel physiological role for cardiac 14-3-3zeta. J Cell Biol. 2004;164:1009–20.

36. Zhu H, Li Y. YSK1 is activated by the Golgi matrix protein GM130 and plays a role in cell migration through its substrate beta1-integrin-mediated activation of PDGFR-beta and alphavbeta1-integrin-mediated activation of PDGFR-beta and potentiating of growth factor signals. J Cell Sci. 2012;125:5269–79.

37. Zhu H, Li Y. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol. 2012;12:39–45.

38. Deutsch DB, Lavine JA, Suoh S, Krautkramer KA, Rabaglia ME, Spencer JM, et al. FoxM1 is up-regulated by obesity and stimulates beta-cell proliferation. Mol Endocrinol. 2010;24:1822–34.

39. Chai KJ, Seok YM, Kim JH. Bioactive lipoxigenase metabolites stimulation of NADPH oxidases and reactive oxygen species. Mol Cells. 2011;31:1–5.

40. Shen Y, Nar R, Fan AX, Aryan M, Hossain MA, Gurumurthy A, et al. Functional interrelationship between TFIH-I and E2F transcription factors at specific cell cycle gene loci. J Cell Biochem. 2018;119:712–22.

41. Kavanagh DP, Yun HM, Yeo IJ, Cho S, Hong JT, Jeong YS. Peroxiredoxin 6 inhibits osteogenetic differentiation and bone formation through human dental pulp stem cells and induces delayed bone development. Antioxid Redox Signal. 2018;30:1969–82.

42. Zhou Y, Cao X, Yang Y, Wang J, Yang W, Ben P, et al. Glutathione S-transferase P1 prevents sepsis-related high mobility group box-1 protein translocation and release. Front Immunol. 2018;9:268.

43. Wenzel P, Rossmann H, Müller C, Kossmann S, Oelze M, Schulz W, et al. Oxidative preconditioning promotes bone marrow mesenchymal stem cells migration and prevents apoptosis. Cell Biol Int. 2009;33:411–8.

44. Kwon J, Wang A, Burke DJ, Boudreau HE, Lekstrom KJ, Korzeniowska A, et al. Peroxiredoxin 6 (Prdx6) supports NADPH oxidase1 (Nox1)-based superoxide generation and cell migration. Free Radic Biol Med. 2016;96:99–115.

45. Zhong C, Zhuang M, Wang X, Li J, Chen Z, Huang Y, et al. NAD(P)H: quinone oxidoreductase 1 and its reductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol. 2012;12:39–45.

46. Pi J, Bai Y, Zhang Q, Weng V, Floering LM, Daniel K, et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes. 2007;56:1783–91.

47. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.

48. Newsholme P, Morgan D, Abdulkader F, Graciano MF, Oliveira-Emilio HR, Hirata AE, et al. Association of NADPH oxidase with glucose-induced insulin secretion by pancreatic beta-cells. Endocrinology. 2009;150:2197–201.

49. O’Neill S, Brault J, Stasia MJ, Knaus UG. Genetic disorders coupled to ROS deficiency. Redox Biol. 2015;6:135–56.

50. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys. 2007;460:113–21.

51. Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Bluher M, et al. Serine/threonine protein kinase 25 (STK25): a potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol. 2012;12:39–45.

52. Pi J, Bai Y, Zhang Q, Weng V, Floering LM, Daniel K, et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes. 2007;56:1783–91.

53. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.

54. Newsholme P, Morgan D, Abdulkader F, Graciano MF, Oliveira-Emilio HR, Hirata AE, et al. Association of NADPH oxidase with glucose-induced insulin secretion by pancreatic beta-cells. Endocrinology. 2009;150:2197–201.

55. O’Neill S, Brault J, Stasia MJ, Knaus UG. Genetic disorders coupled to ROS deficiency. Redox Biol. 2015;6:135–56.

56. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys. 2007;460:113–21.
64. Barrett CW, Short SP, Williams CS. Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut. Cell Mol Life Sci. 2017;74:607–16.

65. Parsons JL, Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Datta PK, et al. Phosphorylation of PNKP by ATM prevents its proteasomal degradation and enhances resistance to oxidative stress. Nucleic Acids Res. 2012;40:11404–15.

66. Bafort F, Parisi O, Perraudin JP, Jijakli MH. Mode of action of lactoperoxidase as related to its antimicrobial activity: a review. Enzyme Res. 2014;2014:517164.

67. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med. 1999;189:1783–9.

68. Inoue K, Takano H, Shimada A, Satoh M. Metallothionein as an anti-inflammatory mediator. Mediators Inflamm. 2009;2009:101659.

69. Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med. 2016;95:27–42.

70. Laurila JP, Laatikainen LE, Castellone MD, Laukkanen MO. SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression. PLoS One. 2009;4:e5786.

71. Sorensen GL. Surfactant protein D in respiratory and non-respiratory diseases. Front Med (Lausanne). 2018;5:18.

72. Zhang X, Hyer JM, Yu H, D’Silva NJ, Kirkwood KL. DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma. Cancer Res. 2014;74:7191–7.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.